Alector, Inc. (ALEC)
| Market Cap | 240.92M +111.4% |
| Revenue (ttm) | 18.42M -79.2% |
| Net Income | -125.39M |
| EPS | -1.19 |
| Shares Out | 111.03M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 322,309 |
| Open | 2.030 |
| Previous Close | 2.050 |
| Day's Range | 2.030 - 2.205 |
| 52-Week Range | 1.010 - 3.400 |
| Beta | 0.65 |
| Analysts | Buy |
| Price Target | 4.83 (+122.58%) |
| Earnings Date | May 7, 2026 |
About ALEC
Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer’s disease; and AL050, a GCase enzyme replacement therapy in preclinical development for the potential treatment of Parkinson’s disease and Lewy body... [Read more]
Financial Performance
In 2025, Alector's revenue was $21.05 million, a decrease of -79.07% compared to the previous year's $100.56 million. Losses were -$142.93 million, 20.1% more than in 2024.
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for ALEC stock is "Buy." The 12-month stock price target is $4.83, which is an increase of 122.58% from the latest price.
News
Alector reports Q1 EPS (21c), consensus (28c)
Reports Q1 revenue $1.05M, consensus $11.03M. “Over the past seven years, we have built a highly differentiated blood-brain barrier platform with the versatility to deliver antibodies, enzymes, protei...
Alector Reports First Quarter 2026 Financial Results and Provides Business Update
Advancing the Alector Brain Carrier (ABC) platform across multiple therapeutic modalities, including antibodies, enzymes, and siRNA, with continued progress across AL037/AL137 (ABC-enabled antibody fo...
Alector price target raised to $2 from 90c at Morgan Stanley
Morgan Stanley raised the firm’s price target on Alector (ALEC) to $2 from 90c and keeps an Underweight rating on the shares. AL101’s failure in the Phase 2 PROGRESS-AD trial…
Alector to discontinue PROGRESS-AD trial of nivisnebart
Alector (ALEC) confirmed that the Phase 2 PROGRESS-AD trial of nivisnebart in individuals with early Alzheimer’s disease will be discontinued. The decision follows a pre-specified futility analysis co...
Alector to Discontinue Phase 2 PROGRESS-AD Trial of Nivisnebart (AL101/GSK4527226) in Early Alzheimer's Disease Following Interim Futility Analysis
--Independent data monitoring committee (IDMC) determined the trial unlikely to meet primary endpoint – --Alector remains focused on advancing its pipeline of novel ABC-enabled candidates, including ...
Alector upgraded to Overweight from Neutral at Cantor Fitzgerald
Cantor Fitzgerald analyst Pete Stavropoulos upgraded Alector (ALEC) to Overweight from Neutral. The Alector Brain Carrier platform positions Alector to become a major player in the neurodegenerative s...
Alector files $400M mixed securities shelf
16:11 EDT Alector (ALEC) files $400M mixed securities shelf
BTIG upgrades Alector to Buy on shift to novel therapeutics
BTIG analyst Thomas Shrader upgraded Alector (ALEC) to Buy from Neutral with a $6 price target The upgrade reflects the company’s shift in focus to the development of novel therapeutics…
Alector upgraded to Buy from Neutral at BTIG
BTIG upgraded Alector (ALEC) to Buy from Neutral with a $6 price target
Alector Transcript: TD Cowen 46th Annual Health Care Conference
The ABC platform enables efficient delivery of antibodies, enzymes, and siRNAs to the brain, showing strong preclinical efficacy and safety. Lead programs are advancing toward IND, with phase 1 trials planned to demonstrate rapid amyloid clearance in Alzheimer’s patients using subcutaneous dosing.
Alector reports Q4 EPS (34c), consensus (36c)
Reports Q4 revenue $6.2M, consensus $1.96M. “Alector’s (ALEC) strength lies in the combination of a highly differentiated blood-brain barrier platform and a team with deep experience executing complex...
Alector Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Advancing the Alector Brain Carrier (ABC) platform across multiple therapeutic modalities, including antibodies, enzymes, and siRNA, with continued progress across AL137 (ABC-enabled anti-amyloid anti...
Alector to Participate in the TD Cowen 46th Annual Health Care Conference
SOUTH SAN FRANCISCO, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the devastating progre...
Alector price target raised to 90c from 75c at Morgan Stanley
Morgan Stanley raised the firm’s price target on Alector (ALEC) to 90c from 75c and keeps an Underweight rating on the shares. The firm sees a continuation of U.S. small-to-mid…
Alector names Neil Berkley as CFO, Chief Business Officer
Alector (ALEC) announced that Neil Berkley, who has served as Alector’s CBO since March 2024, and CBO and Interim CFO since June 2025, has been appointed CFO, effective December 10,…
Alector Appoints Neil Berkley as Chief Financial Officer and Chief Business Officer
SOUTH SAN FRANCISCO, Calif., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the devastating progre...
Alector Transcript: BofA Securities CNS Therapeutics Virtual Conference 2025
The session highlighted a robust neurodegeneration pipeline leveraging proprietary BBB technology for enhanced brain drug delivery. Key programs include AL137 (anti-amyloid-β antibody) and AL50 (GCase-ERT), with clinical milestones expected from 2025 to 2027. Strong financials support continued development.
Alector to Participate in the Bank of America CNS Therapeutics Conference
SOUTH SAN FRANCISCO, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the devastating progre...
Alector price target lowered to 75c from $1.50 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Alector (ALEC) to 75c from $1.50 and keeps an Underweight rating on the shares. The firm, which is updating its model to…
Alector reports Q3 EPS (34c), consensus (41c)
Reports Q3 revenue $3.26M, consensus $3.49M. “We are well-resourced to advance our portfolio of innovative drug candidates for the treatment of neurodegenerative diseases, with a sharpened focus on ou...
Alector Reports Third Quarter 2025 Financial Results and Provides Business Update
Selected lead candidates AL137 for the company's Alector Brain Carrier (ABC)-enabled anti-amyloid beta antibody in Alzheimer's disease, and AL050 for its ABC-enabled GCase enzyme replacement therapy i...
Alector price target lowered to $5 from $10 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Alector (ALEC) to $5 from $10 and keeps a Buy rating on the shares. The firm removed AL001 from the stock’s valuation…
Alector downgraded to Neutral from Buy at BTIG
BTIG downgraded Alector (ALEC) to Neutral from Buy without a price target after the Phase III miss and discontinuation of the latozinemab program. The firm says the study outcome makes…
Alector downgraded to Market Perform from Outperform at William Blair
William Blair analyst Myles Minter downgraded Alector (ALEC) to Market Perform from Outperform without a price target after the Phase III miss and discontinuation of the latozinemab program. The firm…
Alector downgraded to Neutral from Overweight at Cantor Fitzgerald
Cantor Fitzgerald downgraded Alector (ALEC) to Neutral from Overweight without a price target after the company’s INFRONT-3 trial of latozinemab failed to meet its primary endpoint with no directly po...